Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    DATA COMPILATION
    #PharmaFlow

    Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

    Stock Recap
    #PipelineProspector

    Menu

    Ganciclovir Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 467Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    27/02/2026 Fareva
    Luxembourg
    		 EXCELLA GMBH AND CO KG 16992 GANCICLOVIR SODIUM 2003-11-17 Active II Complete 2013-10-05 2013-09-26
    27/02/2026 Hainan Poly Pharm
    China
    		 HAINAN POLY PHARMACEUTICAL CO LTD 25122 GANCICLOVIR SODIUM 2011-07-13 Inactive II N/A
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.